ANGIODYNAMICS INC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AngioDynamics, Inc. on January 20, 2006, covering events occurring on January 16, 2006. The filing addresses the election of a new director to the Board of Directors and the associated compensation agreement.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation.
Material Changes
- Director Election: Peter J. Graham was elected as a Class III director on January 16, 2006, effective immediately. His term expires at the 2006 annual meeting of stockholders.
- Reason for Vacancy: Mr. Graham was elected to fill the vacancy created by the death of former director Howard S. Stern on December 28, 2005.
- Background: Mr. Graham is the son-in-law of the late Mr. Stern and previously served as the Company's corporate counsel and secretary from 1997 until its spin-off in October 2004. He is currently Senior Vice President-Chief Legal Officer, Global Human Resources and Secretary of E-Z-EM Inc., the Company's former parent.
Compensation and Agreements
In connection with his election, the Company granted Mr. Graham an option under the 2004 Stock and Incentive Award Plan with the following terms:
- Option Grant: 25,000 shares of common stock.
- Exercise Price: $28.43 per share.
- Vesting Schedule: Four equal installments of 6,250 shares on the first four anniversaries of the grant date.
- Standard Director Compensation:
- Annual cash retainer: $24,000.
- Board meeting fees: $1,500 per meeting.
- Committee meeting fees: $750 per meeting.
- Annual option grant: 6,000 shares of common stock (granted following the end of the fiscal year).
The Board has not yet determined the specific committees on which Mr. Graham will serve. There are no reportable transactions between the Company and Mr. Graham under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 25,000 share option grant on potential dilution.
- Confirm the current stock price relative to the $28.43 exercise price to assess the intrinsic value of the grant.
- Review the Company's 2004 Stock and Incentive Award Plan (Exhibit 10.2) for remaining share availability.
- Monitor future announcements regarding Mr. Graham's committee assignments.